Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02495636
Title Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Yale University

lung non-small cell carcinoma


Atezolizumab + Rasdegafusp alfa

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST